Abstract
Measuring of blood sugar and glycated hemoglobin (HbA1c) levels is a standard protocol for screening and monitoring of diabetes mellitus progression. However, blood sugar level is depending on food uptake before taking the measurement and HbA1c life cycle is somehow too tong to be monitored in severe cases. In addition, in condition effecting red blood cell structure or hemoglobin production (hemolytic anemia, thalassemia and thalassemia carrier (40-50%)), HbA1c level is not unrealizable. Therefore, measurementof glycated albumin, which is intermediated indicator outside red blood cell, could improve the way to control diabetes progression and treatment in all populations. The research program “Albumin glycation for diabetes mellitus monitoring” is focusing on development of aptasensor platform for detection of glycated albumin. Three platforms have been developed, which are graphene oxide-aptamer, electrochemical and nanopore sensors. In summary, we successfully developed graphene oxide aptamer and electrochemical platform to detect albumin, glycated albumin and percentage of glycated albumin in clinical samples. Both sensitivity and specificity of our graphene oxide-aptamer platform are higher than those of the commercial available (ELISA). Therefore, our platform has a potential for technology transfer and commercialization.
